An analysis of the natural course of subclinical hyperthyroidism

American Journal of the Medical Sciences

Volumn 337, Issue 4, 2009, Pages 225-232

  Díez, Juan J ^a   Iglesias, Pedro ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL GENERAL DE SEGOVIA   (Spain)

Author keywords

Natural history; Subclinical hyperthyroidism; Survival analysis

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; RADIOACTIVE IODINE; THIONAMIDE; THYROTROPIN; THYROXINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; COURSE EVALUATION; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GOITER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROIDISM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OVERT HYPERTHYROIDISM; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SUBTOTAL THYROIDECTOMY; SURVIVAL TIME; THYROID DISEASE; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROTROPIN RELEASE; BLOOD; DISEASE COURSE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; THYROID GLAND;

AGED; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTHYROIDISM; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; THYROID GLAND; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 65549130576     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318187e16d     Document Type: Article

References (33)

1. Toft AD. Subclinical hyperthyroidism. N Engl J Med 2001;345:512-516
2. Papi G, Pearce EN, Braverman LE, et al. A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only. Am J Med 2005;118:349-361 (Pubitemid 40460991)
3. Biondi B, Palmieri EA, Klain M, et al. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 2005;152:1-9. (Pubitemid 40185448)
4. Cooper DS. Approach to the patient with subclinical hyperthyroidism. J Clin Endocrinol Metab 2007;92:3-9.
5. Eggertsen R, Petersen K, Lundberg PA, et al. Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit. Br Med J 1988;297:1586-1592 (Pubitemid 19002708)
6. Okamura K, Ueda K, Sone H, et al. A sensitive thyroid stimulating hormone assay for screening of thyroid functional disorder in elderly Japanese. J Am Geriatr Soc 1989;37:317-322 (Pubitemid 19084798)
7. Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years. A study in an urban US community. Arch Intern Med 1990;150:785-787
8. Sawin CT, Geller A, Kaplan MM, et al. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 1991;151:165-168
9. Parle JV, Franklyn JA, Cross KW, et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol 1991;34:77-83.
10. Sundbeck G, Jagenburg R, Johansson PM, et al. Clinical significance of low serum thyrotropin concentration by chemiluminometric assay in 85-year-old women and men. Arch Intern Med 1991;151:549-556
11. Canaris GJ, Manowitz NR, Mayor GM, et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534
12. Wilson S, Parle JV, Roberts LM, et al. Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly: a community-based cross-sectional survey. J Clin Endocrinol Metab 2006;91:4809-4816 (Pubitemid 44917312)
13. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-499
14. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-1252 (Pubitemid 24333188)
15. Biondi B, Plamieri EA, Lombardi G, et al. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 2002;137:904-914 (Pubitemid 35416626)
16. Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long-term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996;81:4278-4289 (Pubitemid 26412030)
17. Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin results: a 10-year cohort study. Lancet 2001;358:861-865 (Pubitemid 32900566)
18. Tenerz A, Forberg R, Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? J Intern Med 1990;228:229-233
19. Stott DJ, McLellan AR, Finlayson J, et al. Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at increased risk of developing overt hyperthyroidism. Q J Med 1991;78:77-84.
20. Woeber KA. Observations concerning the natural history of subclinical hyperthyroidism. Thyroid 2005;15:687-691
21. Rosario P. The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clin Endocrinol 2008;68:491-492 (Pubitemid 351257846)
22. Morreale de Escobar G, Escobar del Rey F. Consequences of iodine deficiency for brain development. In: De Vilder J, Morreale de Escobar G, Butz S, et al, editors. Thyroid and brain. Stuttgart: Schattauer Verlag; 2003. p. 33-56.
23. McDermott MT, Woodmansee WW, Haugen BR, et al. The management of subclinical hyperthyroidism by thyroid specialists. Thyroid 2003;13:1133-1139 (Pubitemid 38032398)
24. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291:228-238 (Pubitemid 38082818)
25. Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001;142:838-842 (Pubitemid 33016203)
26. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006;295:1033-1041 (Pubitemid 43313719)
27. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993;77:334-338 (Pubitemid 23230035)
28. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthy-roidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000;85:4701-4705 (Pubitemid 32157655)
29. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994;130:350-356 (Pubitemid 24135720)
30. Gussekloo J, van Exel E, de Craen AJ, et al. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004;292:2591-2599 (Pubitemid 39577515)
31. Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005;165:2467-2472 (Pubitemid 41720007)
32. Völzke H, Schwahn C, Wallaschofski H, et al. The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? J Clin Endocrinol Metab 2007;92:2421-2429
33. Singh S, Duggal J, Molnar J, et al. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 2007;125:41-48 (Pubitemid 351305426)